LEVULAN KERASTICK Rx
Generic Name and Formulations:
Aminolevulinic acid HCl 20%; topical soln; contains alcohol.
Sun Pharmaceutical Industries
Indications for LEVULAN KERASTICK:
In combination with blue light illumination (BLU-U Blue Light Photodynamic Therapy Illuminator), for the treatment of minimally to moderately thick actinic keratoses of the face, scalp, or upper extremities.
Clean and dry affected area. Apply to lesions on either scalp, face, or upper extremities, but not simultaneously. One application and one dose of illumination per treatment site per 8-week treatment session. Face or scalp: illumination (second stage) must take place 14–18hrs after application. Protect treated lesions from sun with a head covering. Upper extremities: occlude treated lesions with low density polyethylene plastic wrap and net dressing; protect from sun with long-sleeved shirt and/or gloves. Illumination (second stage) must take place 3hrs after application. Delay in illumination: protect treated lesions for ≥40hrs; see full labeling. Treated lesions not completely resolved after 8 weeks may be treated a second time.
<18yrs: not established.
Cutaneous photosensitivity at wavelengths of 400–450nm. Porphyria or known allergies to porphyrins.
Avoid exposure of photosensitive treatment sites to sunlight or bright indoor light for ≥40hrs. Avoid applying to eyes, mucous membranes, perilesional skin (no more than 5mm around target lesions). Excessive irritation if applied under occlusion >3hrs. Inherited or acquired coagulation defects. Pregnancy. Nursing mothers.
Increased photosensitivity reaction with concomitant photosensitizing agents (eg, griseofulvin, thiazides, sulfonylureas, phenothiazines, sulfonamides, tetracyclines, St. John's wort).
Local reactions (eg, stinging/burning, erythema, edema, scaling/crusting, itching, erosion, hypo-/hyperpigmentation, oozing/vesiculation, dryness); photosensitivity, transient amnestic episodes (monitor).
Sign Up for Free e-newsletters
- Triplet Regimen Found Most Effective for Relapsed/Refractory Multiple Myeloma
- Integrating Preoperative Oral Care Into Cancer Treatment Plans
- Current Status and Dilemma of Second-line Treatment in Advanced Pancreatic Cancer: Is There a Silver Lining?
- American Association for Cancer Research Releases Its 2018 Annual Report
- Pulmonary Toxicity Increased in Pediatric Hodgkin Lymphoma Treated With Brentuximab Vedotin
- Benefit of Chemotherapy for Breast Cancer Observed With Midrange Gene Assay Score
- Antioxidant Interaction With Cancer Therapy
- Young Survivors of Breast Cancer Report Sexual Quality of Life Declines After Treatment
- Myeloablative Conditioning Effective in AML Secondary to MDS/MPN Prior to Allogeneic HCT
- Insurance Status Influences Overall Survival in Follicular Lymphoma
- Endocrine Society Released Guidelines for Managing Endocrine Disorders in Childhood Cancer Survivors
- Skin Cancer Screening: Are They Effective?
- Metronidazole, Vancomycin Recommended for C Difficile in Pediatric Oncology, HSCT
- CDC: HPV Vaccination Rates on the Rise Among Adolescents
- High-Dose vs Standard-Dose Flu Vaccine in Elderly Receiving Chemotherapy
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|